vs
Barnes & Noble Education, Inc.（BNED）とRevvity（RVTY）の財務データ比較。上の社名をクリックして会社を切り替えられます
Revvityの直近四半期売上が大きい（$772.1M vs $598.2M、Barnes & Noble Education, Inc.の約1.3倍）。Revvityの純利益率が高く（12.7% vs 4.2%、差は8.6%）。Barnes & Noble Education, Inc.の前年同期比売上増加率が高い（6.9% vs 5.9%）。Revvityの直近四半期フリーキャッシュフローが多い（$161.8M vs $61.9M）。過去8四半期でBarnes & Noble Education, Inc.の売上複合成長率が高い（20.0% vs 9.0%）
バーンズ・アンド・ノーブル・エデュケーション傘下のバーンズ・アンド・ノーブル書店は、米国で最も店舗数を擁する書籍小売業者です。現在全米に700店以上の実店舗を展開しており、米国本土で影响力のある書籍小売企業として、長年この分野で事業を展開しています。
レブィティ（Revvity, Inc.）は米国のライフサイエンス・診断事業を手がける企業で、製薬およびバイオテクノロジー業界を主な顧客とし、特に新たな細胞治療や遺伝子治療の開発に関連するサービス・製品を提供している。前身は多岐にわたる事業を展開してきた老舗企業パーキンエルマーである。
BNED vs RVTY — 直接比較
損益計算書 — Q2 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $598.2M | $772.1M |
| 純利益 | $25.0M | $98.4M |
| 粗利率 | 21.7% | — |
| 営業利益率 | 6.8% | 14.5% |
| 純利益率 | 4.2% | 12.7% |
| 売上前年比 | 6.9% | 5.9% |
| 純利益前年比 | -49.7% | 3.9% |
| EPS（希薄化後） | $0.72 | $0.86 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $598.2M | $772.1M | ||
| Q3 25 | $274.2M | $698.9M | ||
| Q2 25 | $233.0M | $720.3M | ||
| Q1 25 | $419.7M | $664.8M | ||
| Q4 24 | $559.7M | $729.4M | ||
| Q3 24 | $250.9M | $684.0M | ||
| Q2 24 | $192.7M | $691.7M | ||
| Q1 24 | $415.4M | $649.9M |
| Q4 25 | $25.0M | $98.4M | ||
| Q3 25 | $-18.3M | $46.7M | ||
| Q2 25 | $-23.0M | $53.9M | ||
| Q1 25 | $17.9M | $42.2M | ||
| Q4 24 | $43.2M | $94.6M | ||
| Q3 24 | $-103.9M | $94.4M | ||
| Q2 24 | $-41.9M | $55.4M | ||
| Q1 24 | $-9.3M | $26.0M |
| Q4 25 | 21.7% | — | ||
| Q3 25 | 20.2% | 53.6% | ||
| Q2 25 | 30.3% | 54.5% | ||
| Q1 25 | 22.3% | 56.5% | ||
| Q4 24 | 23.0% | — | ||
| Q3 24 | 17.9% | 56.3% | ||
| Q2 24 | 28.7% | 55.7% | ||
| Q1 24 | 24.2% | 54.6% |
| Q4 25 | 6.8% | 14.5% | ||
| Q3 25 | -8.4% | 11.7% | ||
| Q2 25 | -4.9% | 12.6% | ||
| Q1 25 | 4.5% | 10.9% | ||
| Q4 24 | 8.4% | 16.3% | ||
| Q3 24 | -15.4% | 14.3% | ||
| Q2 24 | -16.3% | 12.4% | ||
| Q1 24 | 0.4% | 6.8% |
| Q4 25 | 4.2% | 12.7% | ||
| Q3 25 | -6.7% | 6.7% | ||
| Q2 25 | -9.9% | 7.5% | ||
| Q1 25 | 4.3% | 6.4% | ||
| Q4 24 | 7.7% | 13.0% | ||
| Q3 24 | -41.4% | 13.8% | ||
| Q2 24 | -21.7% | 8.0% | ||
| Q1 24 | -2.2% | 4.0% |
| Q4 25 | $0.72 | $0.86 | ||
| Q3 25 | $-0.54 | $0.40 | ||
| Q2 25 | $2.97 | $0.46 | ||
| Q1 25 | $0.59 | $0.35 | ||
| Q4 24 | $1.63 | $0.77 | ||
| Q3 24 | $-7.69 | $0.77 | ||
| Q2 24 | $-15.68 | $0.45 | ||
| Q1 24 | $-3.49 | $0.21 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $11.7M | $919.9M |
| 総負債低いほど良い | $122.5M | — |
| 株主資本純資産 | $283.2M | $7.3B |
| 総資産 | $1.1B | $12.2B |
| 負債/資本比率低いほどレバレッジが低い | 0.43× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $11.7M | $919.9M | ||
| Q3 25 | $7.3M | $931.4M | ||
| Q2 25 | $9.1M | $991.8M | ||
| Q1 25 | $9.2M | $1.1B | ||
| Q4 24 | $11.6M | $1.2B | ||
| Q3 24 | $8.2M | $1.2B | ||
| Q2 24 | $10.5M | $2.0B | ||
| Q1 24 | $8.1M | $1.7B |
| Q4 25 | $122.5M | — | ||
| Q3 25 | $170.0M | — | ||
| Q2 25 | $103.1M | — | ||
| Q1 25 | $141.2M | — | ||
| Q4 24 | $177.6M | — | ||
| Q3 24 | $221.9M | — | ||
| Q2 24 | $196.3M | — | ||
| Q1 24 | $30.2M | — |
| Q4 25 | $283.2M | $7.3B | ||
| Q3 25 | $256.5M | $7.4B | ||
| Q2 25 | $272.2M | $7.6B | ||
| Q1 25 | $292.9M | $7.6B | ||
| Q4 24 | $211.4M | $7.7B | ||
| Q3 24 | $149.8M | $7.9B | ||
| Q2 24 | $80.4M | $7.9B | ||
| Q1 24 | $121.5M | $7.8B |
| Q4 25 | $1.1B | $12.2B | ||
| Q3 25 | $950.8M | $12.1B | ||
| Q2 25 | $790.3M | $12.4B | ||
| Q1 25 | $1.1B | $12.4B | ||
| Q4 24 | $1.0B | $12.4B | ||
| Q3 24 | $973.2M | $12.8B | ||
| Q2 24 | $909.9M | $13.4B | ||
| Q1 24 | $1.2B | $13.4B |
| Q4 25 | 0.43× | — | ||
| Q3 25 | 0.66× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.48× | — | ||
| Q4 24 | 0.84× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 2.44× | — | ||
| Q1 24 | 0.25× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $66.2M | $182.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $61.9M | $161.8M |
| FCFマージンFCF / 売上 | 10.4% | 21.0% |
| 設備投資強度設備投資 / 売上 | 0.7% | 2.6% |
| キャッシュ転換率営業CF / 純利益 | 2.65× | 1.85× |
| 直近12ヶ月FCF直近4四半期 | $-4.6M | $509.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $66.2M | $182.0M | ||
| Q3 25 | $-67.6M | $138.5M | ||
| Q2 25 | $52.6M | $134.3M | ||
| Q1 25 | $-41.9M | $128.2M | ||
| Q4 24 | $47.4M | $174.2M | ||
| Q3 24 | $-143.5M | $147.9M | ||
| Q2 24 | $81.7M | $158.6M | ||
| Q1 24 | $-35.8M | $147.6M |
| Q4 25 | $61.9M | $161.8M | ||
| Q3 25 | $-71.3M | $120.0M | ||
| Q2 25 | $49.5M | $115.5M | ||
| Q1 25 | $-44.7M | $112.2M | ||
| Q4 24 | $44.4M | $149.8M | ||
| Q3 24 | $-147.5M | $125.6M | ||
| Q2 24 | $79.1M | $136.6M | ||
| Q1 24 | $-39.0M | $129.7M |
| Q4 25 | 10.4% | 21.0% | ||
| Q3 25 | -26.0% | 17.2% | ||
| Q2 25 | 21.3% | 16.0% | ||
| Q1 25 | -10.7% | 16.9% | ||
| Q4 24 | 7.9% | 20.5% | ||
| Q3 24 | -58.8% | 18.4% | ||
| Q2 24 | 41.1% | 19.7% | ||
| Q1 24 | -9.4% | 20.0% |
| Q4 25 | 0.7% | 2.6% | ||
| Q3 25 | 1.4% | 2.6% | ||
| Q2 25 | 1.3% | 2.6% | ||
| Q1 25 | 0.7% | 2.4% | ||
| Q4 24 | 0.5% | 3.4% | ||
| Q3 24 | 1.6% | 3.3% | ||
| Q2 24 | 1.4% | 3.2% | ||
| Q1 24 | 0.8% | 2.7% |
| Q4 25 | 2.65× | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | -2.34× | 3.03× | ||
| Q4 24 | 1.10× | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
BNED
| Course Materials Product | $459.3M | 77% |
| General Merchandise Product | $112.9M | 19% |
| Serviceand Other | $26.1M | 4% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
